Roche sees net profit swell amid cancer drug success

January 30, 2014

Swiss pharmaceuticals giant Roche on Thursday posted an 18-percent hike in net profit for 2013, driven particularly by rising sales of its cancer-fighting drugs.

The made a of 11.4 billion Swiss francs (9.3 billion euros, $12.7 billion) for the full year, Roche said in a statement.

"2013 was a very good year for Roche," company chief executive Severin Schwan said in the statement.

The picture could have been even rosier without the negative impact of exchange rates: in local currencies the company's net profit swelled 22 percent in 2013.

Sales meanwhile rose three percent to 46.8 billion francs on an operating profit up four percent at 17.9 billion, the group said.

The sales figure ticked in slightly above the expectations of analysts polled by the AWP financial news service, who had anticipated the company to cash in 46.5 billion in sales.

The hike was attributed to rising demand for Roche's biggest cancer-fighting medicines, as well as drugs used in the areas of immunology and ophthalmology and for diagnostics tests.

The company, the world-leader in , has been swelling its portfolio with new treatments like Kadcyla, for women with a particularly aggressive form of , and lukemia drug Gazyva, both approved in the United States last year.

The company said saw its sales jump 10 percent in the United States and 12 percent in emerging economies.

The picture was bleaker in Europe and Japan, where sales grew just two percent.

"We exceeded our financial targets with strong demand for our existing products and positive uptake of recently launched medicines and diagnostics," Schwan said.

He highlighted especially the company's launch of two new drugs, Perjeta and Kadcyla, for women with a particularly aggressive form of breast cancer.

Looking forward, the group said it in 2014 expected to see "low- to mid-single digit growth" in , in terms of constant exchange rates.

The company's board meanwhile proposed dishing out a dividend of 7.80 Swiss francs to shareholders on the 2013 earnings, up six percent from the year before.

The proposed dividend however missed the expectations of analysts, who had anticipated a dividend of 7.91 Swiss francs.

Following the news, Roche's share price fell 1.30 percent to 235.90 francs a piece in morning trading, as the main Swiss market index fell just 0.62 percent.

Explore further: Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

Related Stories

Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

April 11, 2013
Swiss drug giant Roche said Thursday that heightened demand for its Tamiflu drug amid a severe flu season, as well as for its cancer medicines had sent its first-quarter sales up five percent, beating analyst expectations.

Novartis Q4 net profit rises to $2.0 billion

January 29, 2014
Swiss drug maker Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs.

Cancer drugs give Roche a 2012 profit boost

January 30, 2013
Growing demand for its cancer medicines and diagnostic tests used by clinical laboratories helped Swiss drug maker Roche Holding AG post a modest 2.4 percent increase in full-year profits.

Swiss pharma Novartis ups full-year sales outlook (Update)

October 22, 2013
Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...

Roche profits drop on one-off costs

July 26, 2012
(AP) — One-off charges at Swiss drugmaker Roche Holding AG on Thursday pushed first-half net profits down 17 percent, but strong sales of cancer drugs and cost-cutting contributed to a rise in core operating figures.

Amgen Q4 profit leaps 30 percent on higher sales (Update)

January 28, 2014
Amgen Inc.'s fourth-quarter profit jumped 30 percent due to higher sales for nearly all its drugs, an acquisition and a tax benefit.

Recommended for you

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.